Filed in archive
Developments
, News
, Treatment
by Gloria Gamat on November 6, 2007
Positive results of a comparator study of once-weekly exenatide long-acting release (LAR) injection and byetta® (exenatide) injection taken twice daily in patients with type 2 diabetes have recently been announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc..
Indicated for use twice a day in adults with type 2 diabetes who are unsuccessful at controlling their blood sugar levels using common oral diabetes medications - BYETTA® - is the first and only FDA-approved incretin mimetic approved in April 2005 by the FDA.

Now, the once-weekly exenatide long-acting release (LAR) injection is still in the pipeline which Amylin (and its collaborators) expect to file for FDA approval in mid-2009.
While we have heard so many positive feedback from those using BYETTA®, now it is even getting better with the new version.
Find more details from the Amylin Pharma press release.
[Photo Credit: NY Times]
Once-weekly exenatide, an investigational drug, showed a statistically significant improvement in A1C of approximately 1.9 percentage points from baseline, compared to an improvement of approximately 1.5 percentage points for BYETTA®.
Approximately three out of four subjects treated with once-weekly exenatide achieved an A1C of 7 percent or less. A1C of less than 7 percent is the target for good glucose control as recommended by the American Diabetes Association.
Indicated for use twice a day in adults with type 2 diabetes who are unsuccessful at controlling their blood sugar levels using common oral diabetes medications - BYETTA® - is the first and only FDA-approved incretin mimetic approved in April 2005 by the FDA.

Now, the once-weekly exenatide long-acting release (LAR) injection is still in the pipeline which Amylin (and its collaborators) expect to file for FDA approval in mid-2009.
While we have heard so many positive feedback from those using BYETTA®, now it is even getting better with the new version.
Find more details from the Amylin Pharma press release.
[Photo Credit: NY Times]
Tags:
onceweekly
exenatide
longacting
release
LAR
injection
BYETTA®
exenatide
injection
type
2
diabetes
5
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/100648
Mr Wong
Vote for Once-weekly Exenatide Long-acting Release (LAR) Injection Found Superior Over Twice-Daily BYETTA® (exenatide) Injection:
|
Rating: 8.50 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |









